AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Innovation Article
PDF (709.5 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Commentary | Open Access

Dual PD‐1/LAG‐3 Blockade in Breast Cancer: Navigating Benefit and Risk

Kaixiang Feng1, Fanxiang Yin1, Mengting Chen2, Zongbi Yi3 ( )
Translational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
School of Biological Sciences, University of Southampton, Southampton, Hampshire, UK
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China
Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Innovation
Volume 5 Issue 5,
November 2026
Article number: e70088
DOI: 10.1002/cai2.70088

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Feng K, Yin F, Chen M, et al. Dual PD‐1/LAG‐3 Blockade in Breast Cancer: Navigating Benefit and Risk. Cancer Innovation, 2026, 5(5): e70088. https://doi.org/10.1002/cai2.70088

11

Views

1

Downloads

0

Crossref

0

Web of Science

0

Scopus
Received: 14 September 2026
Revised: 13 October 2026
Accepted: 14 October 2026
Published: 27 October 2026
© 2026 The Author(s). Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.